Angiographical follow-up after radioactive "Cold Ends" stent implantation: a multicenter trial.
BACKGROUND
Radioactive stents with an activity of 0.75 to 12 microCi have shown >40% edge restenosis due to neointimal hyperplasia and negative remodeling. This trial evaluated whether radioactive Cold Ends stents might resolve edge restenosis by preventing remodeling at the injured extremities.


RESULTS
The 25-mm long (15-mm radioactive center and 5-mm nonradioactive ends) Cold Ends stents had an activity of 3 to 12 microCi at implantation. Forty-three stents were implanted in 43 patients with de novo native coronary artery disease. Two procedural, 1 subacute, and 1 late stent thrombosis occurred. A restenosis rate of 22% was observed with a shift of the restenosis, usually occurring at the stent edges of radioactive stents, into the Cold Ends stents. The most severe restenosis occurred at the transition zone from radioactive to nonradioactive segments, a region located in dose fall-off.


CONCLUSIONS
Cold Ends stents did not resolve edge restenosis.
Wardeh
A J
AJ
Thoraxcenter Rotterdam, Daniel den Hoed Cancer Center, University Hospital Rotterdam, Rotterdam, The Netherlands.
Albiero
R
R
Kay
I P
IP
Knook
A H M
AH
Wijns
W
W
Kozuma
K
K
Nishida
T
T
Ferrero
V
V
Levendag
P C
PC
van Der Giessen
W J
WJ
Colombo
A
A
Serruys
P W
PW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000209:etiology; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects*; D001918:Brachytherapy / Q000295:instrumentation* / Q000379:methods; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000601:surgery*; D003328:Coronary Thrombosis / Q000209:etiology; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010761:Phosphorus Radioisotopes; D010975:Platelet Aggregation Inhibitors